VPM
STRO icon

Vanguard Portfolio Management’s Sutro Biopharma STRO Stock Holding History

Vanguard Portfolio Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.56M Buy
+197,562
New +$6.16M ﹤0.01% 2351

Other funds holding STRO

AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vanguard Portfolio Management's STRO Position: Q2 2026 in Review

Vanguard Portfolio Management opened a new position in Sutro Biopharma (STRO) in Q2 2026: 197,562 shares worth $6.56M. The stake represents ﹤0.01% of the portfolio and ranks #2351 among its holdings.

55 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Vanguard Portfolio Management held 197,562 shares of Sutro Biopharma worth $6.56M as of Q2 2026.
  • Sutro Biopharma was a new Vanguard Portfolio Management position in Q2 2026.
  • Sutro Biopharma made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2351 holding.
  • 55 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.